- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04884594
AAV8-hCocH for Cocaine Use Disorder
October 31, 2023 updated by: W. Michael Hooten
Intravenous Administration of AAV8-human Cocaine Hydrolase to Treat Cocaine Use Disorder
The purpose of this study is to test the safety of a novel gene viral vector treatment for adults with cocaine use disorder-sustained remission.
This gene regulates an enzyme (cocaine hydrolase) that breaks down cocaine into inactive substances, thereby decreasing the pleasurable feeling this drug usually provides.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a phase-I dose escalation clinical trial testing the safety and MTD of IV administration of AAV8-hCocH to subjects with a history of cocaine use disorder-sustained remission.
Subjects who provide written informed consent, meet entry criteria, and do not have transduction inhibition to AAV8 (pre-existing AAV8 antibodies) will be eligible.
Subjects will be enrolled sequentially every 2-3 months or longer between cohorts.
Dose escalation may be initiated after a single subject has been safely dosed; maximum enzyme expression is anticipated at week 3-4.
This escalation paradigm is intended to minimize the number of subjects exposed to sub-therapeutic doses.
The starting dose is based on the expression and safety of AAV8-CocH in mice, rats and NHP, and previous human experience using AAV8-FVIII IV in hemophilia patients.
The starting dose has a large safety margin (15-fold) from the NOAEL in NHP.
Approximately 7 weeks after an injection, a decision to escalate to the next dose level will be made based on a review of safety parameters and CocH levels by the investigative team.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Brenda Anderson, RN
- Phone Number: (507) 255-7157
- Email: Hooten.william@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Non-treatment seeking male or females ages 18 to 65 years, inclusive.
- DSM-5 diagnosis of cocaine use disorder in sustained remission as confirmed by the PI's review of the medical record.
- Are motivated to abstain from cocaine use during the period of the study, as evidenced both by the judgment of the Investigator or designee and by compliance with the requirement to make regular clinic visits.
- In the opinion of the PI, be in good general health as determined by medical and psychiatric history, general clinical examination, vital signs, and laboratory tests.
- Have provided written informed consent. Subjects should be cooperative, willing and able to participate and adhere to the protocol requirements.
- Have hematology, chemistry, kidney and liver function laboratory tests that are within (+/- 10%) of the current Mayo Clinic standardized normal values.
- Show a baseline EKG that demonstrates normal sinus rhythm and conduction without clinically significant abnormalities or arrhythmias.
- Are willing to return to research area for follow-up.
Exclusion Criteria:
- They show detectable pre-existing immunity to the AAV8 capsid as measured by AAV8 transduction inhibition and AAV8 total antibodies.
- Evidence of HIV or hepatitis of any etiology.
- Creatinine ≥ 1.5 mg/dL.
- Any disease or mental health condition at the physician's discretion that would prevent the subject from fully complying with the requirements of the study. The physician may exclude subjects with active alcohol abuse, other substance abuse or positive urine toxicology screen for substances of abuse.
- Pregnant &/or lactating. All lactating women will be excluded from study participation. Women of child-bearing potential must have a negative pregnancy test performed at screening visit, agree to use birth control throughout the study period, refrain from getting pregnant within the study period and consent to pregnancy testing throughout the study period. Men must agree to use barrier methods of birth control and refrain from fathering children within the next year.
- Morbid obesity (BMI > 40).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AAV8-hCocH Low dose: 2e12 vg/kg
Cohort 1: Participant receives one-time IV administration of low dose 2e12 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
|
2e12 vg/kg single infusion intravenous
6e12vg/kg single infusion intravenous
2e13 vg/kg single infusion intravenous
|
Experimental: AAV8-hCocH Medium dose: 6e12vg/kg
Cohort 2: Participant receives one-time IV administration of medium dose 6e12vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
|
2e12 vg/kg single infusion intravenous
6e12vg/kg single infusion intravenous
2e13 vg/kg single infusion intravenous
|
Experimental: AAV8-hCocH High dose: 2e13 vg/kg
Cohort 3: Participant receives one-time IV administration of high dose 2e13 vg/kg of AAV8-hCocH, with 7 week of follow-up after dose
|
2e12 vg/kg single infusion intravenous
6e12vg/kg single infusion intravenous
2e13 vg/kg single infusion intravenous
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 60 months
|
Number of participants with treatment-related adverse events
|
60 months
|
Change in enzyme expression profile
Time Frame: Baseline, 24 months
|
Serum level of AAV8-hCocH gene expression
|
Baseline, 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: 24 months
|
Cmax is measured as the peak concentration of AAV8 in the blood after intravenous infusion
|
24 months
|
Time of peak concentration (tmax)
Time Frame: 24 months
|
The time to maximum plasma concentration of AAV8 in the blood after intravenous infusion
|
24 months
|
Half-Life (t1/2)
Time Frame: 24 months
|
The time for plasma concentration of AAV8 in the blood to be reduced to exactly half of starting concentration
|
24 months
|
Area under the Concentration-Time Curve (AUC)
Time Frame: 24 months
|
AUC is a measure of the AAV8 serum concentration over time.
Used to characterize drug absorption.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: W. Michael Hooten, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 8, 2021
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
May 7, 2021
First Submitted That Met QC Criteria
May 11, 2021
First Posted (Actual)
May 13, 2021
Study Record Updates
Last Update Posted (Actual)
November 2, 2023
Last Update Submitted That Met QC Criteria
October 31, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-012225
- 5UH3DA042492 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cocaine Dependence, in Remission
-
Temple UniversityNational Institute on Drug Abuse (NIDA)CompletedCocaine-Related Disorders | Cocaine Dependence, in Remission | Cocaine Abuse, in RemissionUnited States
-
University of California, Los AngelesCompletedMethamphetamine Dependence in Remission | Continuous Methamphetamine Dependence
-
University of ArkansasNational Institute on Drug Abuse (NIDA); Baylor College of MedicineCompleted
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence | Cocaine Dependence | Methamphetamine DependenceUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)Completed
-
Tong LeeNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedCocaine Dependence | Methamphetamine DependenceUnited States
-
The University of Texas Health Science Center,...National Institute on Drug Abuse (NIDA)RecruitingAlcohol Dependence | Substance Abuse | Cocaine Dependence | Opiate Dependence | Cocaine AbuseUnited States
-
Johns Hopkins UniversityCompletedBehavior, Addictive | Heroin Dependence | Opioid Dependence | Cocaine Dependence | Cocaine AbuseUnited States
-
Wayne State UniversityNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Heroin Dependence | Cocaine Abuse or DependenceUnited States
-
University of PennsylvaniaCompletedCocaine DependenceUnited States
Clinical Trials on AAV8-hCocH
-
Opus Genetics, IncRecruiting
-
Spark TherapeuticsChildren's Hospital of Philadelphia; University of Pittsburgh; St. James's Hospital... and other collaboratorsTerminated
-
BiogenCompletedX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
Selecta Biosciences, Inc.National Human Genome Research Institute (NHGRI)SuspendedMethylmalonic Acidemia (MMA)United States
-
REGENXBIO Inc.RecruitingDuchenne Muscular DystrophyUnited States
-
Baxalta now part of ShireTerminatedHemophilia BTurkey, Spain
-
Chigenovo Co., LtdRecruitingBietti's Crystalline DystrophyChina
-
NightstaRx Ltd, a Biogen CompanyEnrolling by invitationChoroideremia | X-Linked Retinitis PigmentosaUnited States, United Kingdom, Netherlands, Germany, France, Brazil, Canada, Denmark, Finland
-
National Institute of Allergy and Infectious Diseases...Active, not recruitingHIV-1 Infected Adults With Controlled ViremiaUnited States
-
Baxalta now part of ShireTakeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...Active, not recruitingHemophilia AUnited States, Spain, Hungary, Italy, Germany, Austria, France